A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Recruiting · NCT04985266 · Registry updated 2024-12-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | estrogen-receptor positive breast cancer | Recruiting | Phase 2 | 2024-12-05 | NCT04985266 |
7 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Gustave Roussy, Cancer Campus, Grand Paris | 93 |
| Institute of Cancer Research, United Kingdom | 59 |
| Invitae Corporation | 3 |
| Pfizer | 431 |
| Royal Marsden NHS Foundation Trust | 89 |
| UNICANCER | 111 |
49 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.